| Name | Title | Contact Details |
|---|
Personalized regenerative medicines at scale.
Statistical Center for HIV/AIDS Research and Prevention is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
BioCentriq was founded in 2018 and is a full service CDMO for cell and gene therapy process development and clinical manufacturing. Our ISO-7 certified GMP clinical manufacturing facility is in Newark, NJ. At this facility, we manufacture autologous and allogeneic cell therapies, gene therapies and provide analytical and quality services across several cell types. We offer viral vector production, cell and viral banking and upstream and downstream processing. Additionally, we have the capabilities to manufacture immunotherapies, including monoclonal antibodies and proteins, and vaccines. Our facilities provide full customer access to work in hybrid teams from tech transfer through GMP clinical production. BioCentriq has a BSL-2 certified process development facility located in South Brunswick, NJ to accelerate scale-up and translation activities. We are vendor and technology agnostic and work with our clients to leverage the optimal technology platform for your product through the development process. In support of our full suite of process development and clinical manufacturing services, the team at BioCentriq offers pre-defined and custom workforce development programs as well as full access to our centers during projects in a unique collaborative approach with our expert scientists to knowledge transfer.
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.